Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde · 2026
Two-Year Treatment Outcomes of Simultaneous Intravitreal Dexamethasone and Aflibercept on Diabetic Macular Edema.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lin Tai-Chi, Huang Hsin-Wei, Chung Yu-Chien, Hsu Tsui-Kang, Huang Yi-Ming, Chi Sheng-Chu, Chao Chen-Yu, Tseng Po-Chen
Аннотация
INTRODUCTION: The aim of this study was to report 2-year follow-up data on patients with diabetic macular edema (DME) treated with simultaneous intravitreal dexamethasone (DEX) and aflibercept.
METHODS: Multicenter, retrospective analysis of eyes with DME treated with simultaneous DEX implant and aflibercept injection. Main outcome measures were changes in best-corrected visual acuity (BCVA) and central retinal thickness (CRT) from baseline to 24 months. The secondary endpoint was the interval of retreatment.
RESULTS: Two-year data were available for 52 of the 76 initially included eyes. Compared to baseline, significant improvements in mean BCVA and CRT were observed at 6, 12, 18, and 24 months. An average of 3.26 ± 1.70 intravitreal treatments was required, with a mean retreatment interval of 10.21 ± 6.35 months throughout the study period.
CONCLUSION: Simultaneous intravitreal DEX and aflibercept treatment resulted in sustained improvements in both visual and anatomical outcomes over a 24-month period. This combination therapy represents a valid treatment strategy and demonstrates synergistic efficacy in the management of DME.
METHODS: Multicenter, retrospective analysis of eyes with DME treated with simultaneous DEX implant and aflibercept injection. Main outcome measures were changes in best-corrected visual acuity (BCVA) and central retinal thickness (CRT) from baseline to 24 months. The secondary endpoint was the interval of retreatment.
RESULTS: Two-year data were available for 52 of the 76 initially included eyes. Compared to baseline, significant improvements in mean BCVA and CRT were observed at 6, 12, 18, and 24 months. An average of 3.26 ± 1.70 intravitreal treatments was required, with a mean retreatment interval of 10.21 ± 6.35 months throughout the study period.
CONCLUSION: Simultaneous intravitreal DEX and aflibercept treatment resulted in sustained improvements in both visual and anatomical outcomes over a 24-month period. This combination therapy represents a valid treatment strategy and demonstrates synergistic efficacy in the management of DME.
Предметные рубрики MeSH
HumansRecombinant Fusion ProteinsDexamethasoneReceptors, Vascular Endothelial Growth FactorMacular EdemaIntravitreal InjectionsRetrospective StudiesDiabetic RetinopathyVisual AcuityFemaleMaleTreatment OutcomeTomography, Optical CoherenceFollow-Up StudiesMiddle AgedGlucocorticoidsTime FactorsAgedDrug Therapy, CombinationMacula LuteaFluorescein Angiography